

Patient ID SA00158458	Patient Name SAMPLEREPOR, FMPP2	Birth Date 1970-11-09	Sex M	Age 52
Order Number SA00158458	Client Order Number SA00158458	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 28 Feb 2023 14:00		

Myocarditis/Pericarditis Panel

Echovirus Antibody Panel, Serum

Echovirus 4 Ab

Y038

 **1:8**
 High

Echovirus 7 Ab

Y038

 **1:8**
 High

Echovirus 9 Ab

Y038

 **1:8**
 High

Echovirus 11 Ab

Y038

 **1:8**
 High

Echovirus 30 Ab

Y038

 **1:8**
 High

REFERENCE RANGE: <1:8

INTERPRETIVE CRITERIA:

<1:8 Antibody Not Detected
 ≥ 1:8 Antibody Detected

Single titers ≥ 1:32 are indicative of recent infection. Titers of 1:8 and 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. There is considerable crossreactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Influenza Types A and B Ab, Serum

Influenza A Ab

Y038

 **1:8**
 High

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
Y038	Quest Diagnostics	33608 Ortega Highway, San Juan Capistrano, CA 92675		

Patient ID SA00158458	Patient Name SAMPLEREPORT, FMPP2	Birth Date 1970-11-09	Sex M	Age 52
Order Number SA00158458	Client Order Number SA00158458	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 28 Feb 2023 14:00		

Influenza B Ab

Y038

 **1:8**


REFERENCE RANGE: <1:8

INTERPRETIVE CRITERIA:

 <1:8 Antibody Not Detected
 ≥ 1:8 Antibody Detected

Single titers of ≥ 1:64 are indicative of recent infection. Titers of 1:8 to 1:32 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.



Chlamydomphila pneumoniae Ab IgG/A/M
C. pneumoniae IgG

Y038



 **1:64**

C. pneumoniae IgA

Y038

 **1:16**

C. pneumoniae IgM

Y038

 **1:10**

Interpretation

Y038

**EQUIVOCAL (A)
COMMENT:**

An equivocal interpretation may indicate recent/current infection. Follow-up testing of an additional sample in 2–3 weeks is suggested if clinically warranted.

REFERENCE RANGE:

 IgG <1:64
 IgA <1:16
 IgM <1:10

The immunofluorescent detection of specific antibodies to Chlamydomphila pneumoniae may be

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
Y038	Quest Diagnostics	33608 Ortega Highway, San Juan Capistrano, CA 92675		



Patient ID SA00158458	Patient Name SAMPLEREPORT, FMPP2	Birth Date 1970-11-09	Sex M	Age 52
Order Number SA00158458	Client Order Number SA00158458	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 28 Feb 2023 14:00		

complicated by crossreactive antibodies, non-specific antibody stimulation, or past exposure to similar organisms such as *C. psittaci* and *Chlamydia trachomatis*. IgM titers of 1:10 or greater usually indicate recent infection, and any IgG titer may indicate past exposure. IgA is typically present at low titers during primary infection, but may be elevated in recurrent exposures or in chronic infection.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Received: 01 Mar 2023 08:25

Reported: 01 Mar 2023 09:37

Test Environment
LTCSEQ Template

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
Y038	Quest Diagnostics	33608 Ortega Highway, San Juan Capistrano, CA 92675		